Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 6/20 | 0.73 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25787745 | 0.84 | NNMT (1.00) | NNMTPIK3C3NOTUM | |
| SCHEMBL13991461 | 0.76 | NNMT (0.49) | NNMTPIK3C3SMN1; SMN2 | |
| SCHEMBL25787743 | 0.72 | NNMT (1.00) | NNMTPIK3C3 | |
| SCHEMBL18807214 | 0.68 | NNMT (0.39) | NNMTPOLBSMN1; SMN2 | |
| SCHEMBL14420700 | 0.63 | MAPKAPK2 (0.46) | NNMTPIK3C3SMN1; SMN2 | |
| SCHEMBL28055920 | 0.63 | NNMT (0.43) | NNMT | |
| SCHEMBL14320242 | 0.62 | NNMT (0.46) | NNMTPIK3C3POLB | |
| SCHEMBL17084210 | 0.62 | POLB (0.34) | POLBSMN1; SMN2 | |
| SCHEMBL16196568 | 0.62 | NNMT (0.45) | NNMT | |
| SCHEMBL3803152 | 0.61 | NNMT (0.44) | NNMTNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | NNMT 1318/4885PIK3C3 865/4885NOTUM 2537/4885 |
| US-20100120798-A1 | SUBSTITUTED PIPERIDINES CONTAINING A HETEROARYLAMIDE OR HETEROARYLPHENYL MOIETY | GRK2, GNAO1, PTGER1 | NNMT 2010/4885PIK3C3 2223/4885NOTUM 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.